These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29618795)

  • 1. Dynamic changes in Japan's prevalence of abnormal findings in cervical cervical cytology depending on birth year.
    Ueda Y; Yagi A; Nakayama T; Hirai K; Ikeda S; Sekine M; Miyagi E; Enomoto T
    Sci Rep; 2018 Apr; 8(1):5612. PubMed ID: 29618795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women.
    Tanaka H; Shirasawa H; Shimizu D; Sato N; Ooyama N; Takahashi O; Terada Y
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1597-1601. PubMed ID: 28707725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.
    Yagi A; Ueda Y; Oka E; Nakagawa S; Kimura T; Shimoya K
    Cancer Sci; 2024 Jul; 115(7):2410-2416. PubMed ID: 38698561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
    Simms KT; Hanley SJB; Smith MA; Keane A; Canfell K
    Lancet Public Health; 2020 Apr; 5(4):e223-e234. PubMed ID: 32057317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan.
    Nakagawa S; Ueda Y; Yagi A; Ikeda S; Hiramatsu K; Kimura T
    Cancer Sci; 2020 Jun; 111(6):2156-2162. PubMed ID: 32248632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cancer screening rate differs by HPV vaccination status: An interim analysis.
    Taniguchi M; Ueda Y; Yagi A; Ikeda S; Endo M; Tomimatsu T; Nakayama T; Sekine M; Enomoto T; Kimura T
    Vaccine; 2019 Jul; 37(32):4424-4426. PubMed ID: 31272873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
    Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan.
    Ozawa N; Ito K; Tase T; Metoki H; Yaegashi N
    Tohoku J Exp Med; 2016 Oct; 240(2):147-151. PubMed ID: 27746423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.
    Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T
    Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
    Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
    Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical screening in HPV-vaccinated populations.
    Canfell K
    Climacteric; 2018 Jun; 21(3):227-234. PubMed ID: 29565690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Educational intervention for women in Japan coming of age for cervical cancer screening who grew up during the suspended HPV-vaccination-program.
    Miyoshi A; Ueda Y; Yagi A; Kimura T; Kobayashi E; Hiramatsu K; Nakagawa S; Kimura T
    Hum Vaccin Immunother; 2021 Nov; 17(11):4418-4422. PubMed ID: 35016492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intentions for catch-up HPV vaccination in Japan: an internet survey.
    Nakagawa S; Yagi A; Ueda Y; Ikeda S; Kakuda M; Hiramatsu K; Miyoshi A; Kimura T; Hirai K; Sekine M; Nakayama T; Kobayashi E; Miyagi E; Enomoto T; Kimura T
    Int J Clin Oncol; 2023 Dec; 28(12):1667-1679. PubMed ID: 37776388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.